Savara Inc (NASDAQ:SVRA - Get Free Report)'s stock price traded down 3.9% during trading on Wednesday . The company traded as low as $4.96 and last traded at $4.96. 751,563 shares traded hands during mid-day trading, a decline of 9% from the average session volume of 828,314 shares. The stock had previously closed at $5.16.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on SVRA shares. Piper Sandler boosted their price objective on Savara from $7.00 to $16.00 and gave the stock an "overweight" rating in a research note on Monday, March 4th. JMP Securities initiated coverage on Savara in a research report on Thursday, February 15th. They issued an "outperform" rating and a $8.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Savara has a consensus rating of "Buy" and an average target price of $8.20.
Read Our Latest Analysis on SVRA
Savara Price Performance
The stock's 50 day moving average price is $4.96 and its 200-day moving average price is $4.38. The company has a quick ratio of 15.66, a current ratio of 15.66 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $685.22 million, a PE ratio of -15.03 and a beta of 0.77.
Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. As a group, equities analysts forecast that Savara Inc will post -0.38 EPS for the current year.
Hedge Funds Weigh In On Savara
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Sivia Capital Partners LLC purchased a new stake in Savara in the fourth quarter worth about $169,000. Vanguard Group Inc. raised its holdings in shares of Savara by 2.6% in the 4th quarter. Vanguard Group Inc. now owns 5,914,947 shares of the company's stock valued at $27,800,000 after purchasing an additional 150,346 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Savara in the 4th quarter worth approximately $9,683,000. Goldman Sachs Group Inc. boosted its stake in shares of Savara by 44.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 127,200 shares of the company's stock valued at $598,000 after purchasing an additional 38,895 shares in the last quarter. Finally, Barclays PLC increased its holdings in Savara by 673.4% during the fourth quarter. Barclays PLC now owns 123,956 shares of the company's stock valued at $582,000 after buying an additional 107,928 shares during the period. Institutional investors own 87.93% of the company's stock.
About Savara
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
